Exploring Tualang Honey formulation and Synvisc in rabbit osteoarthritis
INTRODUCTION: Tualang Honey, characterised by its anti-inflammatory and antioxidative properties, presents a novel therapeutic approach to osteoarthritis (OA) management. This study evaluates the efficacy of a Tualang Honey Formulation (THF) (Patent no. MY179303-A) injection, compared to Synvisc,...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Malaysian Orthopaedic Association (MOA)
2024
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/116541/1/116541_Exploring%20Tualang%20Honey%20formulation.pdf http://irep.iium.edu.my/116541/ https://www.morthoj.org/supplements/moa-2024/index.php |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | INTRODUCTION:
Tualang Honey, characterised by its anti-inflammatory and antioxidative properties, presents a novel therapeutic approach to osteoarthritis (OA) management. This study evaluates the efficacy of a Tualang Honey Formulation (THF) (Patent no. MY179303-A) injection, compared to Synvisc, a conventional hyaluronic acid injection, utilising radiographic findings in New Zealand White Rabbits (NZWR) as an OA model.
MATERIALS & METHODS:
A controlled experiment was conducted on 24 OA-induced NZWR. Two experimental groups received THF and Synvisc intraarticularly after 3 weeks post-surgery. The rabbits were then euthanised, and x-rays were taken at 3, 6, 12, and 24 weeks to evaluate joint space narrowing and subchondral sclerosis as indicators of OA progression.
RESULTS:
At 3 and 6 weeks, both groups demonstrated an improving condition in radiographic signs of OA, with no significant difference between them. At 12 weeks, the THF group showed a trend towards better preservation of joint space. By 24 weeks, the radiographic outcomes of THF were comparable to the Synvisc group, with no significant differences of OA progression.
DISCUSSIONS:
The findings suggest that THF may offer a comparable alternative to Synvisc injections in managing OA, with the potential benefits of natural and halal composition and lower cost. However, further studies are needed to assess the long-term clinical outcomes and potential systemic effects of THF.
CONCLUSION:
THF injection is as effective as Synvisc hyaluronic acid injection in reducing radiographic signs of OA in New Zealand White Rabbits at 24 weeks, making it a potential candidate as a viscosupplement in the non-surgical management of OA. |
|---|